Seoul National University Hospital

WEDNESDAY, Dec. 18, 2024 -- The risk for breast cancer is increased with weight gain after age 35 years, according to a research letter recently published in Cancer Biology & Medicine . Katherine De la Torre, from the Seoul National University College of Medicine in South Korea, and colleagues conducted a prospective study to examine the association between weight change throughout distinct lifetime periods and breast cancer risk stratified by menopausal status. A total of 73,192 Korean women (aged 40 to 69 years) were prospectively followed during a median follow-up of 9.2 years. The researchers found 790 new breast cancer cases among 66,870 women with information on weight at 35 years of age. Of these women, 10.72, 32.68, and 35.92 percent had weight loss, maintained stable weight, and gained >5.0 kg, respectively. Compared with women with stable weight, those who gained >10 kg after 35 years of age had an increased risk for breast cancer (hazard ratio, 1.41). Among premenopausal women, gaining 5 to 9.9 kg and ≥10 kg after 35 years of age increased the risk for breast cancer (hazard ratios, 1.89 and 2.23, respectively), with a dose-response effect. Women who gained >0.75 kg per year after age 35 years had an increased risk for breast cancer when a linear weight increment was assumed (hazard ratio, 1.35), but there were no associations based on menopausal status. "Our research points to the critical period after age 35 as a potential window for weight management interventions aimed at breast cancer prevention," lead author Daehee Kang, M.D., Ph.D., also from Seoul National University Hospital, said in a statement. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device "HyperQure". Designed to treat resistant hypertension, HyperQure uses a laparoscopic approach to block the sympathetic nerves surrounding the renal arteries. On October 29, DeepQure announced its participation in TCT 2024 (Transcatheter Cardiovascular Therapeutics), held in Washington, D.C. TCT is one of the world's premier forums for interventional cardiology, drawing over 10,000 heart specialists from more than 100 countries each year to discuss new treatment methods and clinical advancements. The event, running from October 27-30, gathers global leaders in cardiovascular intervention. One of the founders of DeepQure, Professor Chang Wook Jeong, from Seoul National University Hospital, along with researchers from CBSET (Center for Biomedical Science and Engineering Technology)—a GLP-certified research facility that conducted preclinical large-animal studies for FDA submission—attended and presented findings. Professor Jeong presented the ongoing domestic clinical results of HyperQure, initiated in January this year. To date, six hypertensive patients have successfully undergone treatment with HyperQure, and four additional patients are expected to be enrolled before year-end. Dr. Abraham Rami Tzafriri of CBSET presented on "12-Week Safety and Efficacy of New Vascular Bilateral Renal Denitrification Device in Nominal-Dose Pig Model," showcasing HyperQure's safety in animal models, which has led to the device's FDA Investigational Device Exemption (IDE) approval. A company representative stated, "By unveiling the clinical results for HyperQure at TCT 2024, we have demonstrated DeepQure's cutting-edge technological expertise and innovation to a global audience. Building on these positive clinical outcomes, we will launch global clinical trials in November." Contacts: GeunWoo Noh [email protected] SOURCE DeepQure Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Medical education in Asia may be headed to a future where institutions are not only training students but also training AI models. In the HIMSS24 APAC session, "Implementing AI in Healthcare," Dr Hyung-Chul Lee, deputy CIO of Seoul National University Hospital (SNUH), shared how their hospital develops, validates, and implements AI technologies. "For more than 100 years, our hospital has been educating medical students and residents. But now we also have to train LLMs (large language models)." When LLMs eventually made their way to healthcare recently, researchers at SNUH quickly validated their potential application. While LLMs scored high in one of the world's toughest medical examinations and outperformed existing predictive AI models in such use cases as predicting in-hospital mortality and real-time admissions, their ability remains limited. "Our research shows that no LLMs have yet scored higher than 60 [in the Korean Medical License Exam], especially in medical law." "Also, these LLMs have limited ability [in performing] multimodal tasks. For example, if I uploaded images related to ventricular tachycardia – a condition requiring emergency resuscitation – from VitalDB (a multi-parameter vital signs database), even the [latest] ChatGPT-4o [wrongly] answers that it's a normal ECG and no resuscitation is required." Acknowledging the need for LLMs to get fed with more diverse data, Dr Lee and his team built a vector database and a model for fine-tuning search. "We are currently working on vector embedding of all data in our hospital and loading it into the VectorDB." This initiative led to the development of SNUH's in-house LLM platform to safely develop AI models for their clinicians. The LLM service, Dr Lee said, required 40 H100 GPUs and six petabytes of storage. "VectorDB will be our textbook and fine-tuning it will be [in] our curriculum." "I look forward to seeing AI models trained at our hospital and [how these] will change our practice and improve patient outcomes."